ConocoPhillips enters the back half of August with a notably cleaner set of signals than a week ago: the defensive options posture that dominated the prior note has eased, short sellers have cut positions sharply, and analyst upgrades keep landing.
The shift in short positioning is the week's most tangible data point. Bears have retreated aggressively — short interest dropped 31% over the past week to just 1.23% of the free float, down from roughly 1.8% seven days prior and well below the 20-million-share range that held through most of July. The single-session move on August 25, a 16% drop in shares short, is the most decisive step yet in a de-risking trend that has been running since late July. The borrow market echoes this — cost to borrow eased to 0.28%, near its lowest level in 30 days, and availability is essentially unconstrained. There is no meaningful short pressure, and no sign that new bears are stepping in to replace those leaving.
The options picture has also changed materially since the last note. The prior reading flagged a put/call ratio running more than two standard deviations above its 20-day mean — a notably defensive posture. That has unwound. The PCR now stands at 0.84, less than one standard deviation above the 20-day average of 0.78. It remains modestly elevated relative to the summer baseline, but the alarm signal is gone. Where options traders were actively buying downside protection a week ago, the positioning now looks more like routine hedging on a stock that has risen 10% in a month.
The Street is broadly constructive, and has been adding conviction. Morgan Stanley raised its target to $151 from $147 on August 19, reiterating Overweight. Argus lifted to $153. UBS moved to $153 from $143 earlier in the month. Wells Fargo sits at $189 with an Overweight rating. Even Barclays, which trimmed its target to $150 from $155 on August 17, held its Overweight call. The lone holdout is Truist, which carries a Hold with a $130 target — essentially at the current price of $131.84. The consensus mean target of $145 implies around 10% upside. The analyst diffusion score, at the 97th percentile of the ORTEX universe, reflects a lopsided bull case. The bull thesis centers on production growth through 2027, balance-sheet discipline, and the expected continuity from the CEO transition to Andy O'Brien. Bears flag rising capex guidance, lower free cash flow, and potential policy headwinds to Alaskan and domestic operations.
The earnings calendar adds useful context. ConocoPhillips reported on August 6, and the stock gained 2.2% the next day and 8.2% over the following five sessions — a clean positive reaction that likely contributed to the short exodus seen since. The next event is November 5, giving the stock roughly ten weeks of open air before the market has a fresh fundamental anchor. Peers have had a rougher week: APA fell 2.4%, OXY dropped 2.3%, and CVX shed 2.8% on the week. COP gained 1.6% over the same period, a relative outperformance consistent with its year-to-date lead of roughly 44% versus the group.
The setup to watch from here is whether the residual options hedge continues to fade as the stock consolidates post-earnings gains, or whether fresh macro pressure on crude prices re-introduces put demand before the November earnings date.
See the live data behind this article on ORTEX.
Open COP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
